Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aerovate Therapeutics, Inc. (AVTE : NSDQ)
 
 • Company Description   
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.

Number of Employees: 16

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.77 Daily Weekly Monthly
20 Day Moving Average: 66,547 shares
Shares Outstanding: 24.41 (millions)
Market Capitalization: $311.72 (millions)
Beta:
52 Week High: $29.43
52 Week Low: $7.74
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.41% -3.60%
12 Week 31.24% 44.29%
Year To Date 8.31% 32.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
930 Winter Street Suite M-500
-
Waltham,MA 02451
USA
ph: 617-443-2400
fax: -
ir@aerovatetx.com http://aerovatetx.com
 
 • General Corporate Information   
Officers
Timothy P. Noyes - Chief Executive Officer
George A. Eldridge - Chief Financial Officer
Mark Iwicki - Director
Allison Dorval - Director
David Grayzel - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 008064107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 24.41
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $311.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.82 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.92
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -542.86%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -25.25
12/31/21 - -29.20
09/30/21 - -57.16
ROA
03/31/22 - -21.12
12/31/21 - -21.27
09/30/21 - -28.18
Current Ratio
03/31/22 - 35.27
12/31/21 - 68.37
09/30/21 - 47.87
Quick Ratio
03/31/22 - -
12/31/21 - 68.37
09/30/21 - 47.87
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.63
12/31/21 - 7.06
09/30/21 - 7.37
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©